Search
for
Sort by
Research 30 of 1000+
- 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
- Hidradenitis suppurativa and major adverse cardiac events: A systematic review and meta-analysis
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- Minoxidil
- Inflammation as a Modifiable Driver of Ischemic Heart Disease: Mechanisms, Clinical Risks, and Evolving Therapeutic Options
- Drugs that affect autonomic functions or the extrapyramidal system
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- Cells to Surgery Quiz: April 2020
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
- Resistance to the Insulin and Elevated Level of Androgen: A Major Cause of Polycystic Ovary Syndrome
- The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
- Efectos de la disminución de los depósitos tisulares de hierro sobre los factores de riesgo cardiovascular en pacientes con hiperandrogenismo ovárico funcional
- Estimation of biological heart age using cardiovascular magnetic resonance radiomics
- Cardiovascular effects of hormone therapy for prostate cancer
- Hormonal, Medical, and Nonsurgical Aspects of Gender Affirmation
- Advances in the Molecular Pathogenesis and Targeted Therapy of Psoriasis
- Safety Profiles of Tripterygium wilfordii Hook F: A Systematic Review and Meta-Analysis
- ANAIS DO I CONGRESSO MÉDICO DE FORMOSA - COMEF
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Hormone replacement therapy and COVID-19 outcomes in solid organ transplant recipients compared with the general population
- Nitroxide pharmaceutical development for age-related degeneration and disease
- PCSK9: From Nature’s Loss to Patient’s Gain